Autres langues PCL, Inc.

Actions

A241820

KR7241820000

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. Autres places de cotation 21/03/2025			Varia. 5j.	Varia. 1 janv.
6 040,00 ^KRW	-1,63%		-.--%	-

31/05/23	Les actions sud-coréennes clôturent en baisse alors que les incertitudes concernant l'accord sur le plafond de la dette américaine demeurent ; PCL perd 13%.	MT
23/03/23	PCL, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2022	CI

Autres langues

30/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.
30/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding
22/08/24	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding
25/06/24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.
21/06/24	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.
16/01/24	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets
26/12/23	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets
21/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets
15/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.
31/05/23	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%
31/05/23	PCL to Raise 36 Billion Won via Share Issuance
23/03/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
29/12/22	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.
22/12/22	PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4%
21/12/22	PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.
12/12/22	PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.
12/12/22	PCL, Inc. announced that it has received KRW 12.060247575 billion in funding
11/11/22	OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.
11/11/22	PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.
07/04/22	PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index
20/09/21	PCL, Inc.(KOSDAQ:A241820) added to S&P Global BMI Index
23/06/21	MCureX Therapeutics, Inc. announced that it expects to receive KRW 2 billion in funding from OliX Pharmaceuticals,Inc, PCL, Inc., Samyang Holdings Corporation
25/03/21	PCL, Inc. announced that it has received KRW 40.499938368 billion in funding from a group of investors
23/03/21	Datametrex AI Limited Secures Authorization by Health Canada for PCL Inc.'s COVID19 Rapid Antigen Test Kit
18/03/21	PCL, Inc. announced that it expects to receive KRW 40.499938368 billion in funding from a group of investors